Insulin secretion is impaired in type 2 diabetes with the early response being essentially
absent. The loss of this early insulin secretion is hypothesized to be important in the …

The prevalence and medical and economic impact of type 2 diabetes mellitus is increasing
in Western societies. New agents have been developed that act primarily to reduce …

The pharmacokinetics and metabolism of nateglinide were studied in six healthy male
subjects receiving a single oral (120 mg) and intravenous (60 mg) dose of [ 14 C]nateglinide in …

This study assessed the synergistic effects of nateglinide (a nonsulfonylurea d-phenylalanine
derivative) and meals on insulin secretion in 24 patients with type 2 diabetes. Oral doses of …

There is an increasing interest in the simultaneous administration of several probe
substrates to characterize the activity of multiple drug‐metabolizing enzymes, the so‐called “cocktail” …

Drug-induced respiratory depression (DIRD) is a common problem encountered post-operatively
and can persist for days after surgery. It is not always possible to predict the timing or …

The vitamin D binding protein (DBP), alternatively known as Gc-globulin, is a member of the
albumin (ALB) and α-fetoprotein (AFP) gene family. The rat DBP gene is expressed at high …

Background: Opioid-induced respiratory depression is potentially lethal. GAL021 is a
calcium-activated potassium (BK Ca ) channel blocker that causes reversal of opioid-induced …

Nateglinide (Starlix®, SDZ DJN 608 or A‐4166), a new insulinotropic agent, is intended to
be administered prior to a meal in order to improve early insulin release in non‐insulin‐…

This single‐dose, open‐label, parallel‐group study compared the pharmacokinetics and
tolerability of 120 mg doses of nateglinide, a physiologic mealtime glucose regulator for type 2 …